In difficult cases, immunolabeling for more than one melanocytic marker and the demonstration of TSC2 mutations/alterations or TFE3 translocations might be helpful to differentiate PEComa from aberrant HMB-45-positive leiomyosarcoma. This evidence concerns the gene TSC2 and leiomyosarcoma.